Although decline in sexual function is a common reason for ageing men to seek advice regarding testosterone therapy, placebo-controlled trial data have been unable to show a consistent, beneficial role for testosterone. The objective of this study was to determine the effect of testosterone therapy on sexual function in non-obese ageing men with symptoms of androgen deficiency and low-normal serum testosterone levels. A total of 60 men aged 55 years or older in good general health with total testosterone (TT) levels o15 nM, and with symptoms suggestive of androgen deficiency, were randomized in a double-blinded protocol to transdermal testosterone patches or placebo for 12 months. Sexual function was assessed using the International Index of Erectile Function at weeks 0, 26 and 52. In men receiving testosterone TT levels increased by 30% (P ¼ 0.01) and luteinizing hormone decreased by 50% (Po0.001). Relative to placebo, testosterone therapy improved sexual desire (P ¼ 0.04); however other parameters of sexual function including erectile function were unaffected by the treatment. Ageing men in good general health and with symptoms of androgen deficiency and low-normal serum testosterone levels receiving 12 months of transdermal testosterone therapy experienced, relative to placebo, improved sexual desire but no effect on other parameters of sexual function.
Introduction
Declining sexual function is a common reason for ageing men to seek advice regarding the role of testosterone therapy. 1 Placebo-controlled trial data however are equivocal or, at best, report modest beneficial effects on these end points. [2] [3] [4] [5] While reductions in sexual desire and function are frequent accompaniments of male ageing, 6 the extent to which they correlate with testosterone levels is not well defined [7] [8] [9] particularly when testosterone levels remain within the normal young adult range, 10 and the increasing prevalence of erectile dysfunction in older men predominantly relates to neurovascular disease. 11, 12 Most studies of testosterone therapy in older men that have assessed sexual function have failed to demonstrate significant improvement, 2 especially when baseline serum testosterone levels are in the low-normal or normal range. 3 To date only three randomized controlled trials of androgen therapy in ageing men have studied a cohort selected for the presence of symptoms known to be associated with hypoandrogenism, 5, 13, 14 and in these studies only one 5 or two 13, 14 positive symptoms (but not necessarily relating to sexual dysfunction) were required for enrolment.
Aiming to capture subjects representative of those men likely to present to their primary care physicians to discuss, and possibly to be considered as candidates for, testosterone treatment, we conducted a 12-month randomized, placebo-controlled study of transdermal testosterone therapy in healthy, ageing men with symptoms of androgen deficiency and low-normal serum testosterone levels. Men with co-existent medical illnesses (including obesity) that may have influenced total testosterone (TT) levels and/or sexual function were not included. A component of this study aimed to determine the effects of testosterone therapy on self-reported sexual function as measured by a validated questionnaire.
Materials and methods

Subjects
Men aged 55 years and over were recruited by community advertisement. Those volunteers whose mean (of two samples) serum testosterone level was o15 nM, and who were non-obese (body mass index (BMI)o30 kg m À2 and waist circumference (WC) o102 cm) were eligible for randomization. An arbitrary cut-off of 15 nM was selected based on cross-sectional data of TT levels in healthy nonobese men; 15 this figure is approximately equal to one standard deviation below the mean for men aged 20-39 years. Participants were non-smokers who were in good general health and who had symptoms consistent with testosterone deficiency. Subjects had symptoms in each of the categories of mood and cognition (for example, decreased sense of well-being, low mood, lack of motivation, lethargy, perceived poor short-term memory), body composition (for example, diminished muscle mass or strength, gain in fat mass) and sexual dysfunction (for example, poor libido, decline in sexual performance) based on the manifestations of post-pubertal testicular deficiency 16 and the Canadian practice recommendations for screening for androgen deficiency in the ageing men. 17 Because of the possibility that these symptoms of androgen deficiency may have represented depression, a validated screening tool was included in the baseline assessment of the subjects; no subject recorded a score consistent with depression and none were taking antidepressant medication. Although symptoms consistent with androgen deficiency formed part of the inclusion criteria, the study was not powered to determine the effect of testosterone treatment on these symptoms specifically or quality of life in general. Men were excluded if they reported any of the following: excessive alcohol intake, a history of malignancy (excluding non-melanoma skin cancer), serious chronic medical illness including diabetes mellitus, sleep apnoea, or prostate cancer or clinically significant benign prostate disease. Men who had received testosterone therapy in the previous 12 months or had ever had a testosterone implant were not included. Suitable candidates then underwent physical examination and routine laboratory investigations to exclude significant pre-existing medical conditions.
The Southern Health Human Research Ethics Committee approved the project and all subjects gave signed consent. All participants were non-paid volunteers. The study was conducted between May 2001 and April 2004.
Study design
Subjects were treated for 52 weeks with transdermal testosterone or a matching placebo in a doubleblinded randomized protocol. End points were evaluated at 0, 26 and 52 weeks with the questionnaire completed by subjects during visits to the study centre.
Subjects were randomized in a 1:1 ratio by the Clinical Trials Pharmacist, Southern Health, who was responsible for dispensing all individually coded study medication. Compliance was assessed by return of study medication packaging and unused patches, and was calculated to be in excess of 95%.
Study medication
Androderm patches (5.0 mg testosterone) and matching placebo were supplied by Watson Laboratories Inc. (Salt Lake City, UT, USA). A single patch was applied each evening before retiring. Subjects were instructed to choose a site on the thigh, upper arm, abdomen or back for patch application and to rotate the sites of application such that there was an interval of (at least) 7 days before the medication was re-applied to any given site. All subjects were advised to pretreat application sites with triamcinolone acetonide cream 0.02% (Sigma Pharmaceuticals, Australia).
Hormone assays
Blood samples were taken between 0800 and 1100 hours and assayed at study completion. TT was measured on a Beckman Coulter Unicel DXI 800 analyzer utilizing an automated competitive binding immunoenzymatic assay (coefficient of variation (CV) 5.5% at TT levels of 22.4 nM; Beckman Coulter Inc., Fullerton, CA, USA). Luteinizing hormone (LH) was measured by MEIA on an AxSym, Abbott Diagnostics (CV 6.4%, assay sensitivity 0.5 IU l À1 ).
Sexual function questionnaire
Sexual function was assessed at weeks 0, 26 and 52 using the International Index of Erectile Function (IIEF), 18 a validated self-administered tool able to detect treatment-related change in men with erectile dysfunction. 19 These questions score, on an increasing scale, from 0 to 5 whereby 0 represents no sexual activity and/or an unsatisfactory experience and 5 represents frequent successful sexual activity. The questionnaire evaluates five domains of sexual 
Statistical analysis
Assessment of sexual function was a secondary end point for this study for which the primary outcome body composition data have recently been reported. 20 Data were analysed by a per protocol approach. Changes in sexual function between week 0 and week 26, and week 0 and week 52 were analysed with paired t-tests. Differences between treatment groups for the change in each parameter were measured with unpaired t-tests. Changes within each group over time were analysed using repeated-measures analysis of variance with Bonferroni's multiple comparison test. Significance was set at Po0.05; values are given as mean±s.d. or mean (95% confidence intervals).
Results
A total of 618 men contacted the study centre and 134 met the screening criteria. Of them, 121 men underwent physical examination and laboratory investigations following which 13 subjects were excluded and 15 men chose not to participate further. 62 of the remaining 93 men had baseline TT values o15 nM and were eligible for randomization.
Baseline characteristics of the subjects randomized to the testosterone (n ¼ 31) and placebo (n ¼ 31) groups are outlined in Table 1 . Treatment groups were well matched with respect to all sexual function parameters.
One subject in each group chose not to commence treatment. 13 subjects in the testosterone group prematurely discontinued treatment; 10 due to skin irritation, 1 due to an unrelated illness and 2 for personal reasons. Five men in the placebo group withdrew; two for skin intolerance, two due to unrelated inter-current illness and one for personal reasons. Baseline characteristics for the men completing the study are given in Table 1 . Subjects who withdrew from the study were of similar age and BMI to subjects completing the study and had comparable baseline TT and LH levels and sexual function scores (data not shown).
As published previously, 20 in response to testosterone, TT levels increased significantly by 30% (by 4-17.7 ± 1.2 nM) in the testosterone group between weeks 0 and 52 (P ¼ 0.014) whereas LH levels fell by 50% in response to testosterone therapy (Po0.001) and were unchanged in the placebo group.
Sexual function
The IIEF was scored by all subjects completing the study (Table 2) . One subject in the testosterone and three in the placebo group used erectile dysfunction treatments during the course of the study and were excluded from the analysis. The mean erectile function score at week 0 in both groups did not differ and was consistent with a classification of moderate erectile dysfunction. There was a trend to improved erectile function in the placebo group at Testosterone and sexual function in ageing men CA Allan et al week 52 (P ¼ 0.07) but the change between groups was not significant. Analysis of the week 26 results supported this finding (data not shown). Orgasmic function was not influenced by testosterone therapy at either week 26 or 52. Sexual desire (the frequency and level of sexual desire experienced) was similar in the groups at baseline and was significantly higher in the testosterone group at week 52 when compared to week 0 (Po0.001); no change was seen in the placebo group and the difference in change between the groups was significant (P ¼ 0.04). The increase in sexual desire from baseline in the testosterone group was significant at both weeks 26 (Po0.05) and 52 (Po0.001). Across time intercourse satisfaction did not change in the testosteronetreated group but increased in the placebo group (P ¼ 0.04); however there were no between-treatment differences. Overall satisfaction with sexual function did not change in either group at any time point during the study.
Discussion
In this double-blinded trial of testosterone vs placebo in ageing men we specifically recruited subjects who, although objectively in good general health, regarded themselves as having suboptimal health in the areas of mood and cognition, muscle strength and body composition, and sexual function. We aimed to identify this cohort of older men as representative of those who may be considered by their doctor as candidates for androgen replacement. Our testosterone treatment aimed to increase serum TT within the normal range rather than into the supraphysiological range wherein pharmacological effects of testosterone may be seen. We achieved this aim as serum TT increased by 30% into the middle of the healthy young adult male reference range 20 with a reciprocal 50% decline in serum LH serving as a biomarker of increased serum androgenic activity. Men in the testosterone-treated group experienced a significant improvement in sexual desire that was not seen with placebo, however other parameters of sexual function were not influenced by testosterone therapy. Classification of the cohort using the IIEF, a validated questionnaire used to detect treatmentrelated change in men with erectile dysfunction, showed a mean baseline erectile function domain score consistent with moderate erectile dysfunction. We were not, however, able to demonstrate a significant effect of testosterone therapy on overall sexual or erectile function, in agreement with other trials including subjects with comparable baseline testosterone levels, 2, 4 and consistent with a proposed serum testosterone threshold for optimal erectile function (12 nM) that is lower than the baseline TT levels of our subjects (mean 14 nM; lowest baseline value 9.9 nM). 3 Others have also proposed a notional threshold level of serum testosterone for optimal sexual function, 21 beyond which little or no benefit on libido or erectile function is derived from further increasing testosterone levels. Consistent with this, and in contrast to our findings, significant improvement in overall sexual function was documented in profoundly hypogonadal men (mean baseline testosterone 2.7 nM) 22 of comparable age to our subjects after 30 days of testosterone replacement. Our study participants may thus have had baseline TT levels above the threshold required for optimum sexual function for all domains but sexual desire, despite the presence of suggestive symptoms. The wide confidence intervals for the parameter of erectile function however warrant validation of this finding in larger studies; on post hoc power calculations the study was not sufficiently powered for this parameter.
A meta-analysis of testosterone treatment in men with erectile dysfunction and borderline low serum TT did suggest a beneficial effect of further elevation of serum TT when compared to placebo, 23 however Data are shown as mean (95% confidence interval). P-value refers to the difference between groups for the change in each study parameter over 52 weeks.
Testosterone and sexual function in ageing men CA Allan et al the confounding effects of baseline TT levels and the magnitude of change in serum TT were not considered. A subsequent meta-analysis examining the role of baseline TT values was able to show that the effect of testosterone therapy on erectile function was related to baseline testosterone levels. 3 A study of incremental intramuscular testosterone doses in older men with experimentally induced hypogonadotropic hypogonadism resulted in TT levels ranging from low-normal to supraphysiological range. 24 On post hoc analysis, the change in overall sexual function and erections upon waking, but not spontaneous erections, was related to testosterone dose (with an effect seen in the group that received 300 vs 25 mg of intramuscular testosterone weekly for 20 weeks). It is possible that the modest magnitude of increase in serum TT achieved in our, and other, placebo-controlled trials was not great enough to elicit change in overall sexual function.
An improvement in sexual desire, in addition to a positive effect on sexual motivation and erections, was seen in older men with mean baseline testosterone levels of 8.1 nM who received 100 mg per day testosterone gel (increasing serum testosterone to420 nM). 5 In that study a comparative group receiving transdermal testosterone (2 Â 2.5 mg patches per day) also showed an improvement in sexual desire but this was not different to the change seen in the placebo group. We are not aware, however, of other placebo-controlled trials that have shown an improvement in sexual desire in ageing men with testosterone levels in the low-normal range treated with physiological testosterone therapy. 4 A meta-analysis of studies that examined the effect of testosterone on sexual desire (including a broad spectrum of ages, testosterone levels, patient characteristics-specifically pertaining to the baseline level of sexual function, and treatment regimens) found a lower serum testosterone threshold for libido than erectile function. 3 Our data in fact suggest a reversal of these thresholds, although they are consistent with these authors' suggestion that the effect of testosterone treatment on libido is not as closely related to a threshold value as is the effect of treatment on erectile function. 3 In sexually active older men libido (more so than other parameters of sexual function) was found to be improved in relation to the dose of testosterone administered 24 whereas no effect was seen in young men, suggesting both a dose-and an age-related difference in sexual responsiveness to testosterone therapy.
Men in this study had baseline TT levels in the low-normal range. Our ability to select for healthy men with lower TT levels was significantly influenced by the exclusion of obese men (as classified by either BMI or WC), 25 in keeping with the primary body composition end points of the study. 20 Within the original cohort screened for the study, obese men (albeit with a mean BMI of 27 kg m À2 ) were 1.92 times more likely to have TT levels o8 nM than nonobese (Po0.001; 8% of obese vs 0.8% of non-obese men). Thus, restricting our cohort to non-obese men (mean BMI o25 kg m À2 ) has limited our ability to include men with low (o8 nM) testosterone levels. The relationship between TT and obesity is consistent with a previous study of testosterone therapy in ageing men whereby the (mean) BMI of men with (mean) baseline testosterone levels of 8 nM was 30 kg m
À2
. 5 A limitation of the current study is the number of subjects completing the active arm of the study as a result of a higher than expected dropout rate in the men receiving testosterone. The reason for subject dropout in this group was mostly related to patch intolerance (manifesting as a skin reaction confirmed by the study investigators) suggesting that this rather than a perceived lack of benefit was the reason for discontinuation from the study. These data are reported in detail in the paper reporting primary outcome data. 20 Primary outcomes were powered on the basis of expected intolerance to transdermal preparations in some men, 20 however the imbalance of discontinuations between the groups is unexplained. Our choice of testosterone preparation was determined by availability and access to a suitable placebo preparation; newer preparations afford improved opportunities to study these important effects of testosterone therapy in older men.
In summary, in this group of healthy ageing men selected to represent those who may seek advice regarding the use of testosterone therapy (nonspecific symptoms of androgen deficiency and low-normal serum testosterone levels), and with exclusion of medical conditions known to affect sexual function, 12 months of transdermal testosterone therapy, relative to placebo, improved sexual desire but did not affect other parameters of sexual function. It is possible that selecting for a cohort of men with lower baseline testosterone levels and/or achieving a greater change in serum testosterone levels with treatment may demonstrate a more significant effect on sexual function. These findings are of particular importance given that many men seek advice regarding the role of testosterone therapy for symptoms related to sexual function, especially erectile dysfunction and low libido, and will serve to inform the design of future studies addressing this important issue. 
